PulpFixin(R) Launches Investment Offering on StartEngine, Inviting Investors to Help Build the Next Generation of Sustainable Lab Materials

September 11, 2026 11:20 AM

PulpFixin®, an innovator in sustainable laboratory products, announces the official launch of its investment offering on StartEngine, marking an important milestone in the company's growth and its mission to bring more sustainable materials to modern science.Founded in 2024 by industry veterans from the biotech and pharmaceutical supplies industry, PulpFixin is developing a growing portfolio of high-performance, pulp-based products designed to...

Read more

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

September 11, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update."During the first half of 2026, we continued to advance GelrinC® on multiple fronts as we build toward important clinical and commercial milestones in the U.S. and Europe,"...

Read more

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 7:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.The presentation, featuring Robert Berman, Chief Executive Officer of enVVeno Medical, provides an overview of the Company and its innovative enVVe® System, as well as recent corporate and clinical...

Read more

Therabene Appoints Oscar L. Kashala, M.D., Ph.D., D.Sc., as President and to Board of Directors

September 10, 2026 5:40 PM

Therabene, Inc., a biotechnology company developing next-generation inhibitors and targeted protein degraders for difficult-to-treat cancers, today announced the appointment of Oscar L. Kashala, M.D., Ph.D., D.Sc., as President of Therabene and a member of its Board of Directors, effective September 4, 2026. Dr. Kashala will continue to serve as the Company's Chief Medical Officer.Dr. Kashala joined Therabene in August 2025 and has played a...

Read more

Faron Announces R&D Day

September 10, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that it will host an R&D Day for investors, analysts and media on 8 October 2026 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST).The event will provide an opportunity for Faron's senior management team, together with leading...

Read more

Q1 Report - Focused Execution Driving Growth

September 9, 2026 12:10 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Q1 (May 2026 - July 2026) (comparison figures are for the same period 2025/2026)Net sales amounted to KSEK 4,043(2,596), corresponding to an increase of 56%. In local currency, net sales increased by 57%.Operating Loss (EBIT) amounted to KSEK -20,334 (-19,334) including KSEK 2,200 (0) in restructuring costs.Cash flow from operating activities amounted to KSEK -16,100 (- 17,196).At the...

Read more

Biovica Resolves on a Fully Guaranteed Rights Issue of SEK 29.2 Million

September 9, 2026 12:05 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - INSIDE INFORMATION: The board of directors of Biovica International AB (publ) ("Biovica" or the "Company") has today resolved, subject to subsequent approval by an extraordinary general meeting, to carry out a new share issue of B-shares of approximately SEK 29.2 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price has...

Read more

Notice of Extra General Meeting in Biovica International AB

September 9, 2026 12:00 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Wednesday 30 September 2026, at 14:30 CEST at Baker McKenzie Advokatbyrå's office at Mäster Samuelsgatan 17, 111 44, in Stockholm.Right to attend and notificationShareholders who wish to attend the extra general meeting must:i. on the record...

Read more

BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to Australia

September 9, 2026 8:35 AM

BrYet US, Inc. ("BrYet"), a biotechnology innovator focused on developing potentially curative therapies for advanced cancers, today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet's manufacturing subsidiary is located.BrYet logo. / Source: BrYet US, Inc. (EZ Newswire) ...

Read more

Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers

September 9, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has completed formal qualification to become a supplier for five in-vitro diagnostics (IVD) manufacturers ("Dx Test-Makers"). Each of these five Dx Test-Makers are considered to be one of the ten largest such companies by revenues, and Microbix is pleased to have successfully completed their supplier audit &...

Read more

BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to Australia

September 9, 2026 12:00 AM

BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on developing potentially curative therapies for advanced cancers - today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet's manufacturing subsidiary is located.The milestone clears an important manufacturing...

Read more

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

September 8, 2026 10:20 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technologyThe agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful pilot-scale...

Read more

RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements

September 8, 2026 7:02 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its RMTG's Cellgenic division has commenced local commercial arrangements in Colombia, including steps to establish local representation and to develop relationships with physicians and medical providers in permitted channels.The Colombia...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

September 7, 2026 11:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)Non-UK issuerX2....

Read more

Faron Pharmaceuticals Ltd: Holding(s) In Company

September 4, 2026 6:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares:Faron Pharmaceuticals Oy1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an "X")An acquisition or disposal of shares An...

Read more

USDA Deregulates Darling 54 After Six-Year Federal Review

September 3, 2026 1:45 PM

American Chestnut Restoration, Inc. (ACR), a 501(c)(3) nonprofit, volunteer-run organization dedicated to restoring the American chestnut, welcomes the U.S. Department of Agriculture's (USDA) decision to deregulate Darling 54, a blight-tolerant American chestnut developed and tested over decades.The decision follows extensive laboratory and field research, USDA review beginning in January 2020, nationwide public comments, detailed plant pest...

Read more

Cellgenic Establishes Local Commercial Presence in Brazil

September 3, 2026 7:01 AM

Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its Cellgenic division has expanded its commercial presence in Brazil through local representation, physician-facing commercial support, and related infrastructure intended to support product distribution in permitted channels. Brazil is an...

Read more

Synexis, LLC and Zee Company Partner to Advance Food Safety Through Proactive, Continuous Pathogen Control

September 2, 2026 11:50 AM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, today announced a strategic collaboration with Zee Company, a member of the Vincit Group, one of the nation's leading providers of food safety, sanitation, and intervention solutions serving food and beverage manufacturers throughout the United States. Together, the companies will expand access to Synexis' patented DHP® technology to food and beverage processing...

Read more

Ayrmid Appoints Ideogen for Omisirge(R) in EMEA

September 1, 2026 8:00 AM

Ayrmid Ltd. ("Ayrmid" or the "Company"), parent company of Gamida Cell Inc., today announced the appointment of Ideogen Group GmbH ("Ideogen") as its exclusive distributor for Omisirge® (omidubicel-onlv). Under the agreement, Ideogen is granted exclusive rights to launch a managed access program for Omisirge across 55 markets in Europe (excluding Greece and Cyprus), the Middle East and North Africa (MENA), and the Commonwealth of Independent...

Read more

RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint

September 1, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the commencement of Cellgenic commercial activity in Peru through the establishment of local commercial arrangements, including exclusive representation arrangements in permitted channels.The Peru announcement extends Cellgenic's Latin American...

Read more